SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 24.88-1.3%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (2240)5/8/1998 8:25:00 PM
From: Michael P. Michaud  Read Replies (4) of 9523
 
I just love these analysts who "maintain and outperform rating of PFE and a 12 month price target of $120 per share"
Thread, follow me on this one. Merck, which is a great drug company and all, is a "steal" at $117 because the PE is low. What they don't tell you is that 5 of their big selling drugs expire by the year 2000 (I found this info from S & P's Investors Monthly newsletter I get from Fidelity).
PFE on the other hand has "no major patent expirations for the next 5 years" (though BKNY3 did note here that Cardura expires relatively soon).....In addition, Pfe's pipeline has potentially 10-20 blockbuster drugs in it, not counting Viagra's huge success. But joe brokerage houses get all nervous because the PE is too high and they downgrade or "maintain an outperform" rating giving it a shitty price target.
My opinion is that we, as investors, look to the future, and the future is bright for PFE. I can only own a few stocks given my humble occupation and salary, and I only want to own the best.
Mike
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext